Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03757637
Other study ID # 201712196RIND
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2018
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source National Taiwan University Hospital
Contact Yeur-Hur Lai
Phone 886-2-23123456
Email laiyhwk@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Despite the good prognosis of patients with differentiated thyroid carcinomas (DTC), the diagnosis of cancer, fear of cancer recurrence and its side effects might still bring impacts on patients' quality of life and daily function. Purposes: This is a two-phase study. Phase I will aim to examine the current concerns of patients' physical-, psychological, care needs, and physical and psychological function in DTC patients within one year of diagnosis, and identify factors related to patients' physical and psychological functions. Phase II will be a three-group randomized control trail (RCT). The aims will be develop two intervention programs: Nurse-led Survivorship Care Program (NLSCP, Exp-1) and Information & Communication Technology (ICT) Supported Healthy Active Program (ICT supported HAP, Exp-2), and compare the effects of the two intervention groups and control group of their effects on the variables in the above mentioned four dimensions (physical, psychological, care needs, function) in newly diagnosed DTC patients receiving total thyroidectomy. Methods: Phase I is a cross-sectional survey study and to examine the current status of physical distress (e.g., fatigue, pain), psychological distress (e.g., depression, body-image), care needs, and psychological & physical functions. Phase II is a 6-month three-group RCT with 12 month follow-up of its effects. There will have 5 intervention sections during the first 6 month. Control group will be case manager care only. The NLSCP will receive face-to-face or telephone education by trained nurse. The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For both Exp groups, the first 2 sections of interventions will be all delivered face-to-face for helping them to be familiar with the operation system. Patients in the ICT supported HAP group can raise their concerns or questions through APP and receive intervention through App interactively. The outcomes will be assessed at 5 time points: time before first intervention (baseline assessment), 4-5 week before intervention, 3-, 6-, and 12 months. Expected Outcome: We expect this study can help us better understanding DTC patients' impacts and care needs. The comparison of three groups of intervention will also help us to identify the best model to decrease distress and enhance life function for them.


Description:

Phase I is a cross-sectional survey study (first year) with the specific aims to examine the current status of physical distress (fatigue, sleep dysfunction, other symptoms), psychological distress (fear of cancer recurrence, depression, body-image), care needs, and psychological & physical functions in DTC patients diagnosed within three years. We will also examine these factors of their relationship with physical and psychological function by short-form -12. Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. Eligible subjects will be those newly diagnosed DTC patients with total thyroidectomy. A stratified randomization by age (age 45 as cut-off point) and gender would be conducted. Although the different intervention designs in the two intervention groups (NLSCP & ICT supported HAP). The three groups, control and two intervention groups (Exp-1 & Exp-2) will all receive the hospital routine and case manager's care. The three groups will receive baseline assessment before first intervention during hospitalization. We will first build up the contents and operable programs for two interventions groups: nurse-led survivorship care program (NLSCP/ Exp-1) and ICT supported HAP (ICT supported HAP/ Exp-2). Both intervention groups will also receive routine case manager care too. For both intervention groups, there will have 5 intervention sections during the first 6 month, including one day before hospital discharge post-operation, 5-6th week and 2-, 3-, 5- month post operation, known as intervention 1-5, respectively.


Recruitment information / eligibility

Status Recruiting
Enrollment 380
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - newly diagnosed DTC patients - after received thyroid tumor excision operation (total thyroidectomy) Exclusion Criteria: - primary unknown - conscious unclear - recurrence or with bone meta

Study Design


Intervention

Other:
NLSCP
Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
ICT supported HAP
Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.

Locations

Country Name City State
Taiwan Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C. Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (27)

Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006 Jun;60(6):631-7. doi: 10.1016/j.jpsychores.2005.10.020. — View Citation

Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S383-412. doi: 10.1002/acr.20541. No abstract available. — View Citation

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. — View Citation

Chen CL, Liao MN, Chen SC, Chan PL, Chen SC. Body image and its predictors in breast cancer patients receiving surgery. Cancer Nurs. 2012 Sep-Oct;35(5):E10-6. doi: 10.1097/NCC.0b013e3182336f8b. — View Citation

Chen ML, Chang HK, Yeh CH. Anxiety and depression in Taiwanese cancer patients with and without pain. J Adv Nurs. 2000 Oct;32(4):944-51. — View Citation

Chen SC, Huang BS, Lin CY, Fan KH, Chang JT, Wu SC, Lai YH. Psychosocial effects of a skin camouflage program in female survivors with head and neck cancer: A randomized controlled trial. Psychooncology. 2017 Sep;26(9):1376-1383. doi: 10.1002/pon.4308. Epub 2016 Dec 2. — View Citation

Chen SC, Lai YH, Liao CT, Chang JT, Lin CY, Fan KH, Huang BS. Supportive care needs in newly diagnosed oral cavity cancer patients receiving radiation therapy. Psychooncology. 2013 Jun;22(6):1220-8. doi: 10.1002/pon.3126. Epub 2012 Jun 25. — View Citation

Chen SC, Lai YH, Liao CT, Lin CC, Chang JT. Changes of symptoms and depression in oral cavity cancer patients receiving radiation therapy. Oral Oncol. 2010 Jul;46(7):509-13. doi: 10.1016/j.oraloncology.2010.02.024. Epub 2010 Mar 21. — View Citation

Chou YY, Lai YH, Wang SS, Shun SC. Impact of Fatigue Characteristics on Quality of Life in Patients After Heart Transplantation. J Cardiovasc Nurs. 2017 Nov/Dec;32(6):551-559. doi: 10.1097/JCN.0000000000000400. — View Citation

Fong DY, Lam CL, Mak KK, Lo WS, Lai YK, Ho SY, Lam TH. The Short Form-12 Health Survey was a valid instrument in Chinese adolescents. J Clin Epidemiol. 2010 Sep;63(9):1020-9. doi: 10.1016/j.jclinepi.2009.11.011. Epub 2010 Mar 1. — View Citation

Girgis A, Stojanovski E, Boyes A, King M, Lecathelinais C. The next generation of the supportive care needs survey: a brief screening tool for administration in the clinical oncology setting. Psychooncology. 2012 Aug;21(8):827-35. doi: 10.1002/pon.1973. Epub 2011 Apr 12. — View Citation

Grunfeld EA, Low E, Cooper AF. Cancer survivors' and employers' perceptions of working following cancer treatment. Occup Med (Lond). 2010 Dec;60(8):611-7. doi: 10.1093/occmed/kqq143. Epub 2010 Sep 20. — View Citation

Hann DM, Denniston MM, Baker F. Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res. 2000;9(7):847-54. doi: 10.1023/a:1008900413113. — View Citation

Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998 May;7(4):301-10. doi: 10.1023/a:1024929829627. — View Citation

He Y, Meng Z, Jia Q, Hu F, He X, Tan J, Zhang G, Li X, Zhang J, Zhang Q, Liu L, Zhao L, Li J, Wang Y, Qian Y, Hou S, Liu H, Wang S, Wang R, Zheng W, Hu T, Liu N, Upadhyaya A, Liu Y. Sleep Quality of Patients with Differentiated Thyroid Cancer. PLoS One. 2015 Jun 17;10(6):e0130634. doi: 10.1371/journal.pone.0130634. eCollection 2015. — View Citation

Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001 Jan;37(2):189-97. doi: 10.1016/s0959-8049(00)00353-1. — View Citation

Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979 May;41(3):209-18. doi: 10.1097/00006842-197905000-00004. — View Citation

Hung TM, Lin CR, Chi YC, Lin CY, Chen EY, Kang CJ, Huang SF, Juang YY, Huang CY, Chang JT. Body image in head and neck cancer patients treated with radiotherapy: the impact of surgical procedures. Health Qual Life Outcomes. 2017 Aug 23;15(1):165. doi: 10.1186/s12955-017-0740-7. — View Citation

Liao YC, Liao WY, Shun SC, Yu CJ, Yang PC, Lai YH. Symptoms, psychological distress, and supportive care needs in lung cancer patients. Support Care Cancer. 2011 Nov;19(11):1743-51. doi: 10.1007/s00520-010-1014-7. Epub 2010 Oct 15. — View Citation

Shun SC, Beck SL, Pett MA, Berry PH. Psychometric testing of three Chinese fatigue instruments in Taiwan. J Pain Symptom Manage. 2006 Aug;32(2):155-67. doi: 10.1016/j.jpainsymman.2006.02.011. — View Citation

Shun SC, Beck SL, Pett MA, Richardson SJ. Assessing responsiveness of cancer-related fatigue instruments: distribution-based and individual anchor-based methods. Oncologist. 2007 Apr;12(4):495-504. doi: 10.1634/theoncologist.12-4-495. — View Citation

Shun SC, Yeh KH, Liang JT, Huang J, Chen SC, Lin BR, Lee PH, Lai YH. Unmet supportive care needs of patients with colorectal cancer: significant differences by type D personality. Oncol Nurs Forum. 2014 Jan 1;41(1):E3-11. doi: 10.1188/14.ONF.E3-E11. — View Citation

Sundin EC, Horowitz MJ. Horowitz's Impact of Event Scale evaluation of 20 years of use. Psychosom Med. 2003 Sep-Oct;65(5):870-6. doi: 10.1097/01.psy.0000084835.46074.f0. — View Citation

Tsai PS, Wang SY, Wang MY, Su CT, Yang TT, Huang CJ, Fang SC. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. Qual Life Res. 2005 Oct;14(8):1943-52. doi: 10.1007/s11136-005-4346-x. — View Citation

Van Onselen C, Dunn LB, Lee K, Dodd M, Koetters T, West C, Paul SM, Aouizerat BE, Wara W, Swift P, Miaskowski C. Relationship between mood disturbance and sleep quality in oncology outpatients at the initiation of radiation therapy. Eur J Oncol Nurs. 2010 Dec;14(5):373-9. doi: 10.1016/j.ejon.2009.12.002. Epub 2010 Jan 18. — View Citation

Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003. — View Citation

Zilberg NJ, Weiss DS, Horowitz MJ. Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol. 1982 Jun;50(3):407-14. doi: 10.1037//0022-006x.50.3.407. No abstract available. — View Citation

* Note: There are 27 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Hospital Anxiety & Depression Scale (HADS) The severity of lung cancer patients' anxiety and depression will be measured by the self-reporting HADS. The 14 items of HADS consists of two subscales, include 7 items anxiety and 7 items depression. The score of all items ranges from 0 (not at all) to 3 (always) and the total score of each subscale arerange from 0 to 21, a higher score indicates a higher level of anxiety or depression. Satisfactory psychometrics of the HADS has been shown in cancer populations in Taiwan (Chen et al. 2000). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Fear of Recurrence Inventory The FoR-C is a Chinese version of the original FoR questionnaire. The FoR questionnaire consists of six statements with a five-point response scale from not at all (1), a little, sometimes (2), a lot , and all the time) and one statement with a response scale from 0 (not at all) to 10 (a great deal). The summary of FoR was range from 6 to 40. Higher score indicates a higher level of fear of recurrence. The significance of the FoR was indicated by patients' responses 'a lot' or 'all the time' for the first six statements and the score of 7-10 for the last item, in which case. Current study will use the same approach to determine the cut-off point of the FoR. For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Body Image Scale (BIS) The Body Image Scale (BIS) was developed to assess body image. The 10-item BIS comprised three subscales: affective (e.g. feeling feminine/masculine, physically attractive, or sexually attractive), behavioral (e.g. find it hard to look at youeself naked, avoid people because of appearance), and cognitive (e.g. satisfied with appearance, or with scar). Five items were presented positively and the others were presented negatively. Each item was scored from 0 (not at all) to 3 (very much). The higher overall summary score indicated more symptoms and distress. (Hopwood, Fletcher, Lee, & Al Ghazal, 2001) The BIS has been translated to Chinese and validated to be reliable in cancer patients in Taiwan. Cronbach's a was 0.84-0.94. (Chen, Liao, Chen, Chan, & Chen, 2012; Chen et al., 2017; Hung et al., 2017). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Fatigue Severity Inventory The Fatigue Symptom Inventory (FSI) was developed to assess fatigue in patients with cancer. It's a 14-item self-reported measure designed to assess the intensity (four items), duration (two items), daily pattern (one item) and inference (seven items) of fatigue. The Items assessing intensity and interference are scored on an 11-point Likert-type scale (0 = not at all fatigued/ no inference at all; 10 = as fatigued as I could be/ extreme inference). Two items assessing duration are based on the number of days in the past week patients felt fatigue (0 - 7 days) and the percent of time each day fatigue was present (0 = none of the day; 10 = the entire day). (Hann, Denniston, & Baker, 2000; Hann et al., 1998) The Chinese version of FSI has been validated in patients with cancer and its Cronbach's a was 0.92. (Chou, Lai, Wang, & Shun, 2017; Shun, Beck, Pett, & Berry, 2006; Shun, Beck, Pett, & Richardson, 2007). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Pittsburgh's Sleep Index The PSQI was developed by Buysee in 1989, is used to assess sleep quality on participants' sleep experiences during the past week (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Iincluding seven component scores which are sleep duration, sleep disturbances, sleep latency, daytime functioning, habitual sleep efficiency, sleep quality, and sleep medication. The total PSQI score range is from 0 to 21, and the higher the worse of the sleep. If the total PSQI score is more than 5, the result means the person has sleep problems (Buysse et al., 1989; He et al., 2015; Van Onselen et al., 2010). In Chinese-PSQI, Cronbach's a coefficient for the hospital sample and test-retest reliability were 0.83 and 0.85, respectively (Tsai et al., 2005). Normal and problem sleepers (PSQI total score?5 or >5) had 90% of sensitivity and 87% of specificity in original questionnaire (Buysse et al., 1989) and had 98% of sensitivity and 55% of specificity in Chinese version questionnaire (Tsai et al., 2005). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Brief Supportive Care Needs Survey (SCNS-9) The unmet needs of lung cancer patient will be measured by 9 items SCNS. It consists of 5 domains, include psychological, health system and information, daily living, patient care and sexuality domain. Response options "No need, not applicable (1); No need, satisfied (2); Low need (3); Moderate need (4); High need (5). The sum of item scores within each domain will be calculated and the scores will be transformed to a standardized score 0 to 100, higher score indicate more unmet needs (Girgis, Stojanovski, Boyes, King, & Lecathelinais, 2011). The higher scores representing more unmet needs (McElduff, Boyes, Zucca, & Girgis, 2004). A previous study reported the construct reliability and construct validity of this instrument (Girgis et al, 2011). The Chinese SCNS34 has acceptable psychometric properties in previous lung cancer studies (Liao et al., 2011; Shun et al., 2014). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Short Form 12 (SF-12) The Short Form-12 (SF-12) Health Survey is a shortened version of the 36-item Short Form Health Survey with 12 items. It's a generic and validated self-reported health-related quality-of-life questionnaire. The SF-12 consists of eight-scale scores and two summary measures: physical and mental component summary measures (PCS and MCS). It includes two items on physical functioning, two items on role physical, one item on bodily pain, one item on general health, one item on vitality, one item on social functioning, two items on role emotional, and two items on mental health. (Busija et al., 2011; Fong et al., 2010; Ware et al., 1996) The SF-12 scores are calculated by summing the raw scores and transform to a 0-100 scale. The higher score indicated better health. (Busija et al., 2011) The previous study reported Cronbach's a for the Chinese version of the PCS was 0.62-0.83 and the MCS was 0.75-0.76. (Chou, Lai, Wang, & Shun, 2017; Fong et al., 2010). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Symptom Severity Scale (SSS) Symptom Severity Scale was developed to assess patients' symptom severity, and it will be modified to assess disease and treatment-related symptoms in DTC patients. Each item of this 23-item SSS is rated from 0 to 10, with 0 indicating "no such symptom at all" and 10 indicating "extreme severity of the symptom." The SSS has been validated as a reliable scale (Chen et al., 2010; Chen et al., 2013). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Impact of Event Scale-Revised (IES-R) The IES is developed by Horowitz et al. (1979) and it was further revised. The IES-R can directly assess the impact of cancer to patients and it is based on mechanisms of people's dealing with calamitous life events. This instrument includes two psychological dimensions: intrusion and avoidance, and it has good psychometrics characteristics. The IES is scored on a 0-5 scale with the higher the score, the more the intrusion and the greater the avoidant tendency or avoidance (Sundin & Horowitz, 2003). For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
Primary Illness Perception Questionnaire (IPQ-M) The Illness Perception Questionnaire (IPQ) was developed by Broadbent, Petrie, Main and Weinman (2006) and it is for measuring patients' perception about their illness. Also the IPQ has been proven a good psychometric measurement. The IPQ was later modified by Grunfeld, and Cooper (2010) to assess cancer patients' concerns, perception and barriers of their return to work. The 26-item IPQ-M which consists of two major dimensions: (1) the impacts of cancer and its treatment on work, and (2) illness perceptions in relation to work was an 8-point Likert's scale scoring from 0 to 7 with the higher score indicating more concerns or barriers about RTW. For all groups, we will assess patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery & before their hospital; T2 to T6 = 1, 3, 6, and 12 months after discharge from hospital).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Completed NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Completed NCT04971473 - Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal Phase 3
Recruiting NCT04964284 - Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT05078853 - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Active, not recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Phase 3
Recruiting NCT02638077 - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China N/A
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT03191643 - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer N/A
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT04447183 - The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. Phase 2
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Active, not recruiting NCT04940052 - Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer Phase 3
Recruiting NCT04880798 - Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer N/A
Recruiting NCT05789667 - Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Recruiting NCT05660954 - Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3